Viatris Inc.

In a combined stress scenario where distributor consolidation drives operating margin down 300 bps and debt refinancing increases WACC by 200 bps toward 15.0%, free cash flow available for debt service contracts sharply. Carrying $14.70B in total debt under elevated interest rates would consume operational cash flow, halting share repurchases and forcing dividend reductions. In our supporting enterprise valuation, cash flow discounting under a 13.0448% WACC already results in an equity value of $3.45 per share, demonstrating extreme sensitivity to refinancing spreads and margin contraction.

Narrow

Viatris maintains a Narrow economic moat supported by its extensive global manufacturing footprint, deep regulatory filing capabilities, and established commercial relationships across developed and emerging healthcare markets. The company's platform scale enables it to navigate multi-jurisdictional regulatory frameworks and secure over 100 new product approvals annually, having achieved 70 approvals in the first half of 2026 alone. This continuous replenishment is essential for defending gross margins against annual low-single-digit price deflation inherent in off-patent pharmaceuticals.

The moat is further reinforced by brand recognition in international markets. In Greater China, where Viatris generated $2,332.5M in FY2025 revenue, mature branded medications enjoy strong physician and patient preference in retail out-of-pocket pharmacy channels, partially insulating the portfolio from centralized volume-based procurement price cuts. Similarly, Developed Markets generated $8,514.0M in FY2025, providing essential volume scale across institutional and retail dispensing channels.

Nonetheless, structural limitations prevent Viatris from commanding a Wide economic moat. The company faces high wholesale buyer concentration, with Cencora accounting for 11% of revenue in FY2025, alongside McKesson at 10% and Cardinal Health at 5%. This buying power, coupled with manufacturing compliance vulnerabilities such as the Nashik facility disruption, places ongoing pressure on return on capital and caps pricing power.

Viatris Inc. (VTRS) trades at 6.4x forward earnings against a peer median of 12.2x. Its EV/EBITDA of 7.5x compares with a peer median of 10.5x. The comparison uses 4 peers: Centene Corporation, Baxter International Inc., Charles River Laboratories International Inc. and Moderna Inc., as of 2026-10-08 to 2026-10-10.

We recommend a Reduce rating on Viatris Inc. At the October 9, 2026 price of $17.64, the stock trades at an implied return of -9.81% and a 10.87% premium to intrinsic value.³

While Viatris generates approximately $1.94B in annual free cash flow and maintains strong commercial presence across Developed Markets ($8.51B revenue) and Greater China ($2.33B), its $14.70B debt burden and a 13.04% WACC severely constrain equity accretion.